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352Prognostic Utility of Routine Chimerism Testing
at 2 to 6 Months after Allogeneic Hematopoietic
Cell Transplantation
Ghada I. Mossallam,1 Azza M. Kamel,1 Barry Storer,2,4 Paul J. Martin3,5The utility of routine chimerism analysis as a prognostic indicator of subsequent outcomes after allogeneic
hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens remains controversial.
To address this controversy, routine chimerism test results at 2 to 6 months after HCTwith myeloablative
conditioning regimens were evaluated for association with subsequent risk of chronic graft-versus-host dis-
ease (GVHD), nonrelapse mortality (NRM), relapse, and overall mortality. Only 70 of 1304 patients (5%) had
\95% donor-derived cells in the marrow. Low donor chimerism in the marrow occurred more often in pa-
tients with low-risk diseases compared with those with higher-risk diseases and was significantly associated
with a reduced risk of chronic GVHD. Among 673 patients evaluated, 164 (24%) had\ 85% donor-derived
T cells in the blood. Low donor T cell chimerism was more frequent in patients with low-risk diseases com-
pared with those with higher-risk diseases, in those who received conditioning with busulfan compared with
those who received conditioning with total body irradiation, and in those with lower-grade acute GVHD.
Low donor T cell chimerism in the blood was significantly associated with a reduced risk of chronic
GVHD but not with a reduced risk of relapse, NRM, or overall mortality. Routine testing of chimerism in
the marrow and blood at 2 to 6 months after HCTwith myeloablative conditioning regimens may be helpful
in documentingengraftment in clinical trials, but providesonly limitedprognostic information in clinical practice.
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Chimerism testing can be used to document en-
graftment after allogeneic hematopoietic cell transplan-
tation (HCT) and can be highly useful in the diagnosis
of rejection and recurrentmalignancy. Lineage-specific
analysis increases the sensitivity of themethod andmay
provide more specific information [1,2]. Chimerism
tests demonstrating the persistence of recipient cells
after HCT with nonmyeloablative regimens also can
predict an increased risk of rejection or recurrentmalig-
nancy; however, the role of chimerism analysis as
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6/j.bbmt.2008.12.496outcomes after HCT with myeloablative conditioning
regimens remains controversial. Whereas Lamba
et al. [3] reported higher relapse rates and lower overall
survival (OS) inpatientswithmixed chimerism (MC)on
day 90 afterHCT,Doney et al. [4] found no correlation
between persistence of recipient cells at 2 to 3 months
after HCT and subsequent outcomes in patients who
received amyeloablative conditioning regimen.The re-
sults of Doney et al. are consistent with consensus rec-
ommendations that documentation of chimerism is not
essential after HCT with myeloablative conditioning
regimens and conventional graft-versus-host disease
(GVHD) prophylaxis [1].
To address this controversy, we reviewed results of
routine chimerism tests at 2 to 6 months after HCT
with myeloablative conditioning regimens in a large
cohort of patients, to evaluate whether test results
were associated with subsequent risks of chronic
GVHD, nonrelapse mortality (NRM), recurrent ma-
lignancy, and survival.METHODS
The study cohort included all patients who had
undergone a first allogeneic HCT with the use of
Table 2. Characteristics of Patients Who Underwent Blood
Cell Testing
Characteristic
Entire
Cohort
< 95% Donor
Granulocytes
< 85% Donor
T Cells
Number of patients (%) 673 14 (2) 164 (24)
Patient age, 39 (0 to 66) 34 (1 to 57) 42 (1 to 64)
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Hutchinson Cancer Research Center and had routine
chimerism testing of the marrow (n5 1304) (Table 1)
or of both granulocytes and T cells in the blood
(n 5 673) (Table 2) with the use of sex markers or
molecular markers as part of the departure evaluationTable 1. Characteristics of PatientsWhoUnderwentMarrow
Cell Testing
Characteristic Entire Cohort
< 95% Donor
Marrow Cells
Number of patients (%) 1304 70 (5)
Patient age,
years, median (range)
37 (0 to 66) 41 (0 to 63)
Disease at transplantation, n (%)
Myelodysplastic syndrome 195 10 (5)
Acute myeloid leukemia 300 3 (1)
CML 443 40 (9)
ALL 182 4 (2)
Non-Hodgkin lymphoma
or Hodgkin disease
68 5 (7)
Other 116 8 (7)
Pretransplantation risk
category, n (%)
Low 415 37 (9)
Intermediate 628 25 (4)
High 261 8 (3)
Donor age,
years, median (range)
37 (0 to 81) 40 (1 to 65)
Donor/recipient sex, n (%)*
Male/male 286 10 (4)
Male/female 411 28 (7)
Female/male 457 20 (4)
Female/female 148 12 (8)
Donor type, n (%)
HLA-identical related 649 38 (6)
HLA-mismatched related 108 8 (7)
HLA-matched unrelated 293 13 (4)
HLA-mismatched unrelated 254 11 (4)
Conditioning regimen, n (%)
Cyclophosphamide and TBI 676 26 (4)
Busulfan and cyclophosphamide 375 27 (7)
Busulfan and TBI 43 1 (2)
Busulfan, cyclophosphamide, and TBI 59 1 (2)
Busulfan, cyclophosphamide, and ATG 27 4 (15)
Cyclophosphamide, TBI, and ATG 41 3 (7)
Other containing ATG 55 4 (7)
Other 28 4 (14)
Stem cell
source, n (%)
Bone marrow 1012 57 (6)
Mobilized blood 279 10 (4)
Cord blood 13 3 (23)
GVHD prophylaxis, n (%)
Cyclosporine and methotrexate 1061 63 (6)
Tacrolimus and methotrexate 92 4 (4)
Methotrexate 31 0
Calcineurin inhibitor 92 3 (3)
Calcineurin inhibitor
and MMF
21 0
Other 7 0
Previous acute GVHD, n (%)†
Grade 0-I 292 20 (7)
Grade II 742 36 (5)
Grade III-IV 269 14 (5)
ATG, antithymocyte globulin; MMF, mycophenolate mofetil.
*Two patients received cord blood transplants from 2 donors (1 male
and 1 female).
†GVHD could not be graded in 1 patient because of severe regimen-
related toxicity.
years, median (range)
Disease at transplantation,
n (%)
Myelodysplastic syndrome 164 3 (2) 57 (35)
Acute myeloid leukemia 216 4 (2) 36 (17)
CML 118 3 (3) 52 (44)
ALL 111 0 3 (3)
Other 64 4 (6) 16 (25)
Pretransplantation risk
category, n (%)
Low 144 4 (3) 55 (38)
Intermediate 434 8 (2) 98 (23)
High 95 2 (2) 11 (12)
Donor age,
years, median
(range)
38 (1 to 76) 30 (1 to 60) 38 (5 to 65)
Donor/recipient sex,
n (%)*
Male/male 204 5 (2) 50 (25)
Male/female 155 3 (2) 42 (27)
Female/male 160 2 (1) 39 (24)
Female/female 153 4 (3) 33 (22)
Donor type, n (%)
HLA-identical related 288 10 (3) 79 (27)
HLA-mismatched related 15 0 2 (13)
HLA-matched unrelated 225 3 (1) 63 (28)
HLA-mismatched unrelated 145 1 (1) 20 (14)
Conditioning regimen, n (%)
Cyclophosphamide and TBI 250 2 (1) 13 (5)
Busulfan and
cyclophosphamide
287 6 (2) 106 (37)
Busulfan, cyclophosphamide,
and ATG
42 2 (5) 6 (14)
Cyclophosphamide, TBI,
and ATG
25 0 3 (12)
Other containing ATG 35 2 (6) 20 (57)
Other 34 1 (3) 16 (47)
Source of stem
cells, n (%)
Bone marrow 195 6 (3) 62 (32)
Mobilized blood 460 7 (2) 101 (22)
Cord blood 18 1 (6) 1 (6)
GVHD prophylaxis, n (%)
Cyclosporine plus
methotrexate
437 10 (2) 120 (27)
Tacrolimus plus
methotrexate
157 3 (2) 37 (24)
Methotrexate 3 0 0
Calcineurin inhibitor 43 1 (2) 6 (14)
Calcineurin inhibitor
and MMF
33 0 1 (3)
Previous acute GVHD, n (%)
Grade 0-I 157 5 (3) 56 (36)
Grade II 426 8 (2) 96 (23)
Grade III-IV 90 1 (1) 12 (13)
*One patient received a cord blood transplant from 2 donors (1 male
and 1 female).before their care was transferred from the transplanta-
tion center to the referring physician. Routine testing
was done on a single occasion, and the choice of sam-
ples for testing was dictated by institutional practices,
which changed over time. Transplantations for the pa-
tients who had marrow testing were done between July
354 Biol Blood Marrow Transplant 15:352-359, 2009G. I. Mossallam et al.1988 and September 2006, and transplantations for the
patients who had blood cell testing were done between
September 2000 and September 2006. Testing was
done at a median of 79 days (range, 53 to 188 days) af-
ter HCT. A patient was excluded from further analysis
if the departure testing showed evidence of recurrent
malignancy. Every patient included for consideration
signed an Institutional Review Board–approved in-
formed consent document granting permission to
review medical information for research purposes,
and the Institutional Review Board approved the use
of medical information for this retrospective study.
Blood cells were sorted according to CD33 and
CD3 expression by flow cytometry before chimerism
testing. Nonfractionated aspirated marrow and
fractionated blood cells from patients with sex-
mismatched donors were tested by fluorescent in situ
hybridization with Y-chromosome–specific probes or
with both Y- and X-chromosome–specific probes [5].
Starting in 1998, DNA samples from patients with
same-sex donors were tested by amplification and
semiquantitative analysis of variable-number tandem
repeat loci with informative polymorphisms. Ampli-
fied products were analyzed semiquantitatively after
electrophoresis and silver staining in polyacrylamide
gels [6]. As assessed by mixing experiments, this
method has a sensitivity of 0.1% to 5%, depending
on the relative size of the informative markers. Starting
in 2004, samples from patients with same-sex donors
were tested by multiplex amplification of short tandem
repeat loci with informative polymorphisms (Power-
Plex 16; Promega, Madison, WI). Amplified products
were analyzed quantitatively by capillary electrophore-
sis (ABI 3130x1; Applied Biosystems, Foster City, CA).
This method has at least 0.5% sensitivity, as assessed
by mixing experiments [7]. Pretransplantation samples
from the donor and recipient were routinely included
as controls.
Survival probabilities were estimated according to
the Kaplan-Meier method. Probabilities of recurrent
malignancy, NRM, and chronic GVHD were esti-
mated by the cumulative incidence method. Follow-
up for survival and recurrent malignancy was censored
at the date of last contact or death. Follow-up for
NRM and chronic GVHD was censored at the onset
of recurrent malignancy or date of last contact, which-
ever occurred first. The c2 test or Fisher’s exact test
was used to estimate the statistical significance of cat-
egorical differences. Cox proportional hazards analysis
was used to compare estimated hazard ratios (HRs)
and 95% confidence intervals (CIs) for mortality,
recurrent malignancy, NRM, and chronic GVHD in
patients with and without low donor chimerism. Ad-
justment factors considered were disease risk (low
risk: chronic myeloid leukemia [CML] in the chronic
phase and refractory anemia; high risk: malignant dis-
ease in relapse, refractory anemia with excess blasts intransformation, and CML in blast crisis; intermediate
risk: all other diagnoses), conditioning (busulfan and
cyclophosphamide, cyclophosphamide and total body
irradiation [TBI], and all other regimens), grafting
with growth factor–mobilized blood cells, and grade
II-IV acute GVHD with onset before chimerism
testing.RESULTS
Two factors were considered when defining
a threshold for low donor chimerism. First, the thresh-
old percentage of recipient cells had to be above the
lower limit of sensitivity in reliably detecting these
cells by the assays used for testing (5%), to avoid con-
founding due to false-negative results. Second, a suffi-
cient number of patients with low donor chimerism
was needed to allow reasonable statistical power for
observing associations with clinical outcomes, if possi-
ble. Routine testing of aspirated marrow at 2 to 6
months after HCT found . 5% recipient cells (\
95% donor cells) in only 70 of the 1304 patients tested
(5%) (Table 1). Although this threshold does not pro-
vide optimal statistical power, using a less stringent
definition of low donor chimerism was not feasible,
because of limits in the sensitivity of chimerism tests.
Low donor chimerism (\ 95% donor cells) in the
marrow occurred more frequently in patients with
low-risk diseases (predominantly CML) compared
with those with higher-risk diseases (predominantly
acute leukemia) (P\ .001). The persistence of . 5%
recipient cells was not significantly associated with do-
nor–recipient sex combination, donor–recipient rela-
tionship, conditioning regimen, use of growth
factor–mobilized blood versus marrow, posttransplan-
tation immunosuppressive regimen, or severity of
acute GVHD (Table 1). Correlation with clinical out-
come showed a statistically significant association of
low donor chimerism in the marrow with decreased
subsequent risk of chronic GVHD (HR 5 0.65; 95%
CI 5 0.5 to 0.9; P 5 .02) but not with subsequent
risk of recurrent malignancy, NRM, or overall mortal-
ity (Table 3; Figure 1).
Based on the same considerations used to define
low donor chimerism in the marrow, the presence of
\95% donor-derived cells was used to define low do-
nor chimerism in blood granulocytes. Only 14 of 673
patients (2%) had\ 95% donor-derived granulocytes
in the blood. Low donor chimerism in blood granulo-
cytes occurred too infrequently to enable meaningful
analysis of correlation with transplant characteristics
or clinical outcome (Tables 2 and 3). The percentile
distribution of T cell chimerism suggests that the pres-
ence of\85%donor-derived cells could be used to de-
fine low donor chimerism (Figure 2). Based on this
definition, low donor chimerism (\ 85%) was found
Table 3. Association of Low Donor Chimerism with Subsequent Outcome after HCT*
Overall Mortality Relapse NRM Chronic GVHD
Comparison HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Donor chimerism
in marrow
$ 95% (n 51234) 1.0 .87 1.0 .17 1.0 .90 1.0 .02
< 95% (n 5 70) 0.97 (0.7 to 1.4) 1.35 (0.9 to 2.1) 0.97 (0.6 to 1.7) 0.65 (0.5 to 0.9)
Donor chimerism
in blood granulocytes
$ 95% (n 5 659) 1.0 .38 1.0 .45 1.0 .88 1.0 .30
< 95% (n 5 14) 0.60 (0.2 to 1.9) 0.59 (0.1 to 2.4) 0.90 (0.2 to 3.6) 0.67 (0.3 to 1.4)
Donor chimerism
in blood T cells
$ 85% (n 5 509) 1.0 .02 1.0 .38 1.0 .07 1.0 .02
< 85% (n 5 164) 0.66 (0.5 to 0.9) 0.84 (0.6 to 1.2) 0.62 (0.4 to 1.0) 0.76 (0.6 to 1.0)
*Results do not reflect adjustment for other risk factors.
Biol Blood Marrow Transplant 15:352-359, 2009 355Chimerism Testing after Myeloablative HCTin 164 of the 673 patients (24%) (Table 2). The preva-
lence of lowT cell chimerism was greater in in patients
with CML or myelodysplastic syndrome compared
with those with acute lymphoblastic leukemia (ALL)
(P\ .001), in patients with low-risk diseases compared
with those with high-risk diseases (P \ .001), in
patients who had conditioningwith busulfan compared
with those who had conditioning with TBI (P\ .001),
and in patients with grade 0-1 acute GVHD compared
with thosewith grade III-IVGVHD (P\.001). LowT
cell chimerismoccurred less frequentlywhen the donor
and recipient wereHLA-mismatched (P\.001), and inFigure 1. Clinical outcomes according to lepatients who received a combination of calcineurin in-
hibitor and mycophenolate mofetil compared with
methotrexate after transplantation (P 5 .003). Low T
cell chimerism was not significantly associated with
donor–recipient sex combination, donor–recipient
relationship, or stem cell source (Table 2).
Correlation with clinical outcome demonstrated
a statistically significant association between low
T cell chimerism and subsequent reduced risk of
chronic GVHD (HR 5 0.76; 95% CI 5 0.6 to 1.0;
P 5 .02) (Table 3; Figure 3). This association was
slightly attenuated after adjustment for differences invel of donor chimerism in the marrow.
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Figure 2. Percentile distribution of donor T cell chimerism in the
blood.
356 Biol Blood Marrow Transplant 15:352-359, 2009G. I. Mossallam et al.pretransplantation risk category, conditioning regi-
men, use of mobilized blood cells, and previous grade
II-IV GVHD (HR 5 0.80; 95% CI 5 0.6 to 1.0; P 5
.09). In univariate analysis, low T cell chimerism was
significantly associated with lower overall mortality
(HR 5 0.66; 95% CI 5 0.5 to 0.9; P 5 .02) (TableFigure 3. Clinical outcomes according to level of3; Figure 3), but after adjustment for differences in
disease risk group and conditioning regimen, this asso-
ciation was no longer statistically significant (HR 5
0.77; 95%CI5 0.5 to 1.1; P5 .16). LowT cell chime-
rism showed a trend for association with a lower risk of
NRM (HR5 0.62; 95% CI5 0.4 to 1.0; P5 .07), but
not with an increased risk of recurrent malignancy
(Table 3).
To some extent, the association of low donor chi-
merism in the marrow with a reduced risk of chronic
GVHD could reflect low donor T cell chimerism in
the blood, because aspirated marrow contains an ap-
preciable number of T cells from the blood. To test
this hypothesis, we evaluated the correlation between
donor chimerism levels in the marrow and the blood
in 173 patients who underwent both tests. Low donor
marrow chimerismwas seen in 6 of 47 patients (12.8%)
with low T cell chimerism and in 3 of 126 patients
(2.4%) with high donor T cell chimerism (P 5 .01,
Fisher’s exact test). In these patients, low donor
T cell chimerism was significantly associated with a re-
duced risk of chronic GVHD (HR 5 0.51; 95% CI 5
0.3 to 0.9; P5 .02), but low donor marrow chimerism
was not (HR 5 0.97; 95% CI 5 0.4 to 2.7; P 5 .96).
None of the 509 patients with$ 85% donor T cell
chimerism underwent a second transplantation for
treatment of graft failure, and only 2 of the 164 patientsdonor T cell (CD3) chimerism in the blood.
Biol Blood Marrow Transplant 15:352-359, 2009 357Chimerism Testing after Myeloablative HCT(1.2%) with low donor T cell chimerism underwent
a second transplantation due to poor graft function.
In 1 of these cases, test results on day 81 after the first
transplantation showed 5% to 15% donor-derived
T cells in the blood with 95% to 99% donor-derived
granulocytes, and results on day 160 showed 1% to
5% donor-derived T cells in the blood, again with
95% to 99% donor-derived granulocytes. In the other
case, the results on day 81 after the first transplantation
showed 60% donor-derived T cells in the blood with
77% donor-derived granulocytes, with similar results
seen on day 111.DISCUSSION
In this study, we found that only a small minority
of patients had\95% donor-derived cells in the mar-
row and blood granulocytes at 2 to 6 months after
HCT with a myeloablative conditioning regimen.
Low donor chimerism in the marrow occurred pre-
dominantly in patients with low-risk diseases, such as
chronic-phaseCML, andwas associatedwith a reduced
risk of chronic GVHD. Approximately 25% of the pa-
tients in this study had\85% donor-derived T cells in
the blood at 2 to 6 months after HCT with myeloabla-
tive conditioning regimens. Low donor chimerism in
blood T cells occurred predominantly in patients
with low-risk diseases and was associated with the
absence of TBI in the conditioning regimen and the
absence of acute GVHD. Low donor chimerism in
the marrow and in blood T cells at 2 to 6 months after
HCT with myeloablative conditioning regimens was
significantly associated with a reduced risk of chronic
GVHD but not with reduced risk of recurrent malig-
nancy, NRM, overall mortality, or graft failure neces-
sitating a second transplantation. Routine testing of
chimerism in the marrow and blood at 2 to 6 months
after HCT with myeloablative conditioning regimens
may be helpful in documenting engraftment in clinical
trials but provides only limited prognostic information
in clinical practice.
The threshold of \ 85% donor-derived T cells
used to define low donor chimerism in our study was
selected empirically and may differ from the values
used in other studies. The percentile distribution of
T cell chimerism in our study showed a smooth pro-
gression from low values to high values, with no obvi-
ous break point. The 85% threshold approximates the
inflection of the curve and had no a priori biological
significance.
The absence of previous myelosuppressive treat-
ment before referral for HCT most likely accounts
for the associations of low-risk diseases with low donor
marrow chimerism and of low donor T cell chimerism
at 2 to 6 months after HCT with a myeloablative
conditioning regimen. In this study, low-risk diseasesincluded CML in chronic-phase and refractory ane-
mia, which are almost never treated with high-dose
myelosuppressive treatment. High-risk diseases in-
cluded malignant disease in relapse, refractory anemia
with excess blasts in transformation, and CML in blast
crisis, and intermediate-risk diseases included all other
diagnoses. We acknowledge that some patients in the
intermediate- and high-risk categories did not receive
previous myelosuppressive treatment. We used the
low- and higher-risk categories as surrogates for the
respective absence or presence of previous myelosup-
pressive treatment, although we do not have direct
data demonstrating this correlation. A similar explana-
tion has been invoked for the observation that the
incidence of graft rejection after HCT with nonmye-
loablative conditioning regimens is higher in patients
with low-risk diseases than in those with higher-risk
diseases [8]. These results support the hypothesis
that previous exposure to multiple cycles of myelosup-
pressive chemotherapy increases the susceptibility of
recipient hematopoietic cells and T cells to the effects
of both myeloablative and nonmyeloablative pretrans-
plantation conditioning regimens.
The finding that low donor T cell chimerism
occurred more frequently than low donor myeloid chi-
merism suggests that previous myelosuppressive treat-
ment, the pretransplantation conditioning regimen,
and the effects of acute GVHD have a greater cumula-
tive effect on myeloid cells than on T cells in the recip-
ient. Mattsson et al. [9] reported similar lower levels of
T cell chimerism compared with myeloid chimerism.
Chimerism testing at 2 to 6 months after HCT sug-
gests that the fractionated TBI exposures and doses
of busulfan used in this study had equivalent cumula-
tive effects on recipient myeloid cell but different ef-
fects on recipient T cells. These results indicate that
fractionated TBI has a more potent immunosuppres-
sive effect than busulfan, as demonstrated by other
studies [9]. The association of HLA-mismatching
and acute GVHD with decreased proportions of
persisting recipient T cells and higher levels of donor
T cell chimerism is consistent with the hypothesis
that the targets of acute GVHD include recipient
T cells as well as basal epithelial cells in the skin, bile
duct epithelial cells in the liver, and crypt epithelial
cells in the gastrointestinal tract.
Our results demonstrating that persistence of
recipient cells in the marrow or blood T cells beyond
2 months after HCT is associated with a reduced risk
of chronic GVHD after allogeneic HCTwith myeloa-
blative conditioning regimens are consistent with the
findings of other studies. McCann et al. [10] reported
that patients with MC were at decreased risk for
chronic GVHD after HCT for treatment of aplastic
anemia, whereas Balon et al. [11] reported that the de-
velopment of complete chimerism within the first
3 months after HCT was associated with an increased
358 Biol Blood Marrow Transplant 15:352-359, 2009G. I. Mossallam et al.risk of chronic GVHD. To some extent, low donor
chimerism in aspirated marrow specimens can be
explained by low T cell chimerism in the blood. The
reduced risk of chronic GVHD associated with low
donor chimerism in the blood but not with low donor
chimerism in the marrow in patients who underwent
both tests suggests that low donor T cell chimerism
(or persistence of recipient T cells) represents the
dominant association. Recipient T cells could have
suppressive or veto effects on donor cells that cause
chronic GVHD, thereby inducing a state of tolerance.
Alternatively, the association of high donor T cell chi-
merismwith an increased risk of chronic GVHD could
reflect the activity of some other factor that simulta-
neously eliminates recipient T cells and also induces
chronic GVHD.
The absence of a correlation between low donor
T cell chimerism and the subsequent risk of recurrent
malignancy is somewhat unexpected, because the
persistence of recipient T cells is associated with a de-
creased risk of chronic GVHD, and the development
of chronic GVHD is associated with a decreased risk
of recurrent malignancy. Any increment in risk of re-
current malignancy associated with the observed de-
crease in risk of chronic GVHD in patients with
persisting recipient T cells could have been too small
to measure in a cohort of patients with a variety of ma-
lignant diseases. The absence of a correlation between
low donor marrow chimerism or low donor T cell chi-
merism and the subsequent risk of recurrent malig-
nancy in our study is consistent with results of
several previous studies [4,12-14]. Other studies, how-
ever, have shown an association between the persis-
tence of recipient myeloid cells [15,16] or T cells
[17] after unmanipulated [15,16] or T cell–depleted
[16,17] HCT and an increased risk of recurrent malig-
nancy in patients with CML. Associations between
persistence of recipient cells and increased risk of
recurrent malignancy also have been reported in pa-
tients with acute leukemias [3,18]. Chimerism assays
certainly can be used as a diagnostic indicator of re-
current malignancy, but their utility as a prognostic
indicator of recurrent malignancy depends on the
nature of the malignancy, the intensity of the condi-
tioning regimen [8], and the methods used to prevent
GVHD.
Contrary to results reported by Lamba et al. [3],
our data do not support an association between sur-
vival and low donor T cell chimerism at 2 to 6 months
after HCT with myeloablative conditioning. On the
other hand, we found a trend for an association be-
tween low donor T cell chimerism and reduced risk
of subsequent NRM. This association can be ex-
plained, at least in part, by the reduced risk of chronic
GVHD associated with persistence of recipient
T cells, because chronic GVHD is the primary cause
of late NRM after allogeneic HCT.Our findings do not support an association be-
tween low donor T cell chimerism and a subsequent
risk of graft failure after T cell–replete HCT with
myeloablative conditioning regimens, although other
studies have found such associations [2]. Although
graft rejection can be caused by recipient T cells that
survive the conditioning regimen, the mere presence
of a particular cell population does not allow us to di-
rect inferences concerning its functional capabilities
[19]. Thus, our findings emphasize that the persistence
of recipient T cells after HCT does not necessarily
indicate that rejection is likely to occur. Chimerism
assays certainly can be used as a diagnostic indicator
of rejection, but their utility as a prognostic indicator
of rejection depends on other factors that affect the
risk of rejection, such as the intensity of the condition-
ing regimen and the use of T cell depletion to prevent
GVHD.
To some extent, the association between donor
T cell chimerism and the subsequent risk of chronic
GVHD can be considered when making decisions
about the withdrawal of immunosuppressive treatment
or enrollment of a patient in a clinical trial evaluating
new approaches to preventing chronic GVHD. Rou-
tine chimerism testing at 2 and 6 months after HCT
with myeloablative conditioning regimens also can
be used to document engraftment in clinical trials.
Our results demonstrating the absence of strong corre-
lations with risks of recurrent malignancy, NRM, and
OS apply only for chimerism testing in patients who
have undergone HCTwith a myeloablative condition-
ing regimen, and should not be extrapolated to
patients who have received a nonmyeloablative condi-
tioning regimen [8]. Although our findings apply to
the use of routine chimerism testing for prognostic
purposes, they have no relevance to the use of chime-
rism testing for diagnostic purposes.ACKNOWLEDGMENTS
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